The content on this site is intended for healthcare professionals only
Dr Cohen speaks with ecancertv at ESMO 2016 about the Activ8 trial, which sought to combine cetuximab and chemotherapy with toll-like-receptor agonist motolimod.
He describes the pathways by which motolimod redirects CD8 T cells towards non-immunogenic tumours, though reports the Activ8 trial as a statistically negative trial having not met its end-points.
Thought a negative trial in this instance, he describes the immune activity in a subset of patients who responded best as indicative of motolimods potential for future trials.
GIST tumours and soft tissue sarcomas
OncoAlert Round Up for August 25th - 31st, 2023
Choosing Wisely in radiology Tanzania
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The use of IORT at Universitätsmedizin Mannheim hospital
Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC
Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
